Chardan Capital Estimates Immunic FY2026 Earnings

Key Points

• Chardan Capital has estimated that Immunic, Inc. will report a FY2026 earnings per share of ($0.05), maintaining a "Buy" rating and setting a price target of $13.00 on the stock.
• Immunic's latest quarterly earnings were ($0.20) per share, missing analysts' consensus estimates of ($0.18) by ($0.02).
• Institutional investors own 51.82% of Immunic's stock, with significant increases in holdings by firms like Jane Street Group and Millennium Management.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Chardan Capital issued their FY2026 earnings estimates for Immunic in a report released on Monday, September 29th. Chardan Capital analyst R. Li anticipates that the company will post earnings per share of ($0.05) for the year. Chardan Capital currently has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share.

Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02).

A number of other analysts have also weighed in on IMUX. D. Boral Capital reiterated a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research note on Thursday, September 25th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research note on Friday, September 26th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, Immunic presently has an average rating of "Buy" and an average target price of $9.50.

Immunic Price Performance

NASDAQ:IMUX opened at $0.96 on Thursday. The firm has a market capitalization of $94.70 million, a P/E ratio of -1.02 and a beta of 1.56. Immunic has a 1-year low of $0.56 and a 1-year high of $1.73. The company's fifty day moving average price is $0.89 and its 200-day moving average price is $0.92.

Institutional Trading of Immunic

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its position in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after buying an additional 152,726 shares during the period. Millennium Management LLC lifted its holdings in Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock valued at $580,000 after purchasing an additional 479,846 shares in the last quarter. 683 Capital Management LLC lifted its holdings in Immunic by 28.6% during the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock valued at $981,000 after purchasing an additional 200,000 shares in the last quarter. Aberdeen Group plc purchased a new position in Immunic during the first quarter valued at $1,155,000. Finally, Focus Partners Wealth lifted its holdings in Immunic by 19.1% during the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock valued at $2,816,000 after purchasing an additional 415,104 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.